Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
12,218 total articles
Mark N. Rogers, Executive Vice President and General Counsel of Amkor Technology (AMKR), sold 5,000 shares of common stock on April 16, 2026, for $59.43 per share, generating $297,150. The sale coincided with the exercise of 5,000 employee stock options at $7.40 per share on the same day. Rogers adopted a Rule 10b5-1 trading plan on August 1, 2025,…
Aehr Test Systems director Rhea J. Posedel sold 7,500 shares on April 20, 2026, for $88.09 each, totaling $660,675, according to a Form 4 filing. The company meanwhile reported a record $41 million production order for package-level burn-in of custom AI processor ASICs, posted mixed Q3 2026 results, and recorded strong bookings that lifted backlog …
Dolphin Entertainment Chief Executive William O’Dowd IV acquired 3,200 shares on April 20, 2026, paying a weighted average of $1.524 per share for a total of $4,876. The transaction raises his direct and indirect holdings in the company amid 2025 revenue growth and a cautious market reaction to recent earnings.
CareDx Chief Executive John Walter Hanna Jr. sold 10,282 shares of company stock on April 16, 2026, for a total of $217,155 at $21.12 per share under a Rule 10b5-1 trading plan. The transaction occurred as shares had risen sharply in recent periods. The company recently reported strong fourth-quarter results, provided 2026 revenue guidance above co…
United Therapeutics Chairperson and CEO Martine A. Rothblatt sold 9,500 shares under a pre-arranged 10b5-1 plan on April 17, 2026, generating roughly $5.57 million. The transaction followed an option exercise of 9,500 shares at $146.03 per share, and occurred while the stock traded close to its 52-week high of $607.89 after a 107% gain over the pas…
Hims & Hers Health, Inc. Chief Financial Officer Okupe Oluyemi sold 54,927 shares of Class A common stock across two transactions in mid-April, generating about $1.46 million. The trades were executed under a Rule 10b5-1 plan adopted on May 21, 2025. Mr. Oluyemi also exercised options for 6,184 shares and retains significant direct, indirect an…
Cynthia H. Davis, a director at Citizens, Inc. (NASDAQ:CIA), reported several purchases of the company’s Class A shares across early 2026, including an indirect acquisition of 100 shares on March 25, 2026. Separately, the company’s board approved higher compensation for Chief Executive Officer Jon Stenberg effective April 1, 2026. An InvestingPro n…
Morgan Stanley Chief Legal/Admin Officer Eric F. Grossman sold 11,118 shares of the company's common stock on April 20, 2026, totaling $2,120,758. The sale occurred as the stock traded near its 52-week high and after a year of substantial gains. The bank also reported stronger-than-expected first-quarter results and drew renewed analyst attention, …
Andrew Dakos, President and CEO of Total Return Securities Fund (NASDAQ:SWZ), purchased $68,314 worth of the fund’s common stock across transactions on April 16 and April 17, 2026. The buys, executed at prices between $6.04 and $6.09 per share, come while the stock is trading close to its 52-week low and after a recent Form 4 amendment correcting i…
Jorge Andres Cedron, Chief Legal Officer of Orthofix Medical Inc. (NASDAQ:OFIX), sold 3,743 shares on April 16, 2026 for $47,985 at $12.82 per share to meet tax withholding obligations related to restricted stock unit settlement. The sale was carried out under a pre-authorized sell-to-cover program approved by the Compensation and Talent Developmen…
Cognition Therapeutics President and CEO Lisa Ricciardi bought $10,092 of company stock on April 16, 2026, increasing her direct holdings to 1,715,851 shares. The transaction coincides with the company reporting a reduced net loss for 2025 and plans to engage the FDA on a registrational pathway for zervimesine following positive Phase 2 SHIMMER res…
John Brendan Doyle, chief financial officer of Cognition Therapeutics Inc. (NASDAQ: CGTX), purchased 10,000 shares of the company on April 16, 2026, at $1.13 per share. The transaction increased his direct holdings to 627,509 shares. The buy coincides with strong recent stock performance and company updates showing narrower losses and a plan to pur…
Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics Inc. (NASDAQ: CGTX), bought 10,000 shares on April 16, 2026, paying $1.11 per share for a total of $11,100. The transaction leaves him with 874,906 shares on a direct basis. The purchase comes amid notable share-price momentum and follows the company’s 2025 results, which showed a re…
Exzeo Group CEO Paresh Patel purchased 2,000 shares of company stock on April 17, 2026, for $33,880. The deal increases his direct holdings to 1,618,013 shares. The company reported fourth-quarter and full-year 2025 results in line with analyst expectations, with diluted EPS of $0.25 and quarterly revenue of $53.32 million. Exzeo’s shares rose afte…
Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold 1,000 American depositary shares on April 16, 2026, totaling roughly $160,380. The transactions were carried out under a Rule 10b5-1 trading plan. The company is progressing toward a New Drug Application submission for tinlarebant following positive Phase 3 DRAGON results, prompting severa…
James Mulay, a director at CG Oncology, disposed of 15,600 common shares on April 17, 2026, through a pre-arranged Rule 10b5-1 plan. The sale, executed at a weighted average price of $73.01, generated proceeds of $1,138,956. Mulay had earlier acquired the same shares by exercising vested director stock options at $36.63 per share. The transaction l…
Nathan L. Mata, chief scientific officer of Belite Bio, sold 1,000 American depositary shares on April 17, 2026, generating $161,629 under a Rule 10b5-1 plan adopted December 10, 2025. The transaction coincides with a period of significant stock appreciation and a string of favorable clinical and analyst developments tied to tinlarebant for Stargar…
Entities associated with AE Industrial Partners reported the sale of 5,179,743 shares of Redwire Corp common stock for $55,156,790 across transactions on April 16 and April 17, 2026. The sellers retain an indirect stake of 24,238,608 shares. The share sales occurred while Redwire stock trades amid wide volatility and after the company announced a s…
Mary E. Gross, a director at Unity Bancorp Inc. (NASDAQ: UNTY), sold 2,075 shares on April 17, 2026, realizing $116,220 at $56.0101 per share. The transaction comes as the bank's stock trades close to its 52-week high and follows a first-quarter report that modestly exceeded analyst forecasts on both earnings and revenue. Gross retains direct owner…
Liang Yifan, chief financial officer and corporate secretary of Alpha & Omega Semiconductor Ltd (NASDAQ: AOSL), sold 8,625 common shares on April 17, 2026 under a previously established Rule 10b5-1 plan. The transactions totaled $301,878 at prices between $35.0000 and $35.0200 per share, with a weighted average price of $35.0004. The sale occurred …
Hershey Trust Co., identified as a 10% holder of The Hershey Company (NASDAQ: HSY), sold 20,000 shares of common stock for about $3.85 million across transactions on April 16 and April 17, 2026. The sales, executed at prices between $190.2791 and $194.1778 per share, leave the Trust with substantial direct and indirect holdings, including more than…
EyePoint Chief Medical Officer Ramiro Ribeiro exercised 2,437 stock options and sold the same number of shares on April 17, 2026, generating $36,555 in proceeds. The sale, completed under a Rule 10b5-1 plan, follows a year of strong stock performance even as the company reported a steep revenue decline in Q4 2025 and a large full-year net loss. Sev…
Sheryle Bolton, a member of Tivic Health Systems' board, purchased 10,000 shares of the company's common stock on April 15, 2026, spending $10,400 at $1.04 per share. The trade comes as the stock has rallied 38% in the past week but remains down 56% over six months. Tivic is repositioning itself from consumer devices toward a biopharmaceutical focu…
Harrison James Little, Executive Vice President at Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN), acquired 5,000 shares on April 17, 2026, at $13.19 per share for a total of $65,950. The fund's shares are trading slightly higher at $13.39 and have produced a 22% total return over the past year. After the transaction, Little directly h…
Azar Samak L, GlobalFoundries' Chief Legal Officer, sold 500 ordinary shares on April 16, 2026 under a pre-established Rule 10b5-1 plan, realizing $24,355. The transaction leaves her with 17,494 shares. The sale falls within an exemption to a lock-up agreement that expires May 10, 2026. The semiconductor maker is also navigating patent litigation, …
